Aspen Neuroscience’s cash reserves have been fertilized with a $115 million series C fundraise that will enrich the biotech’s ongoing trial of a regenerative cell therapy for Parkinson’s disease.
The raise will power Aspen’s phase 1/2 study of ANPD001, a therapy that turns patients’ skin cells into new neurons that are then transplanted into their brains to treat Parkinson’s.
“We’re seeing improvements in both motor and non-motor symptoms, which is sort of the holy grail in Parkinson’s,” Aspen CEO Damien McDevitt, Ph.D., told Fierce Biotech.
Aspen has dosed 14 patients in the phase 1/2 trial so far, McDevitt added, and the company is now looking ahead to a phase 3 study that he hopes will kick off next year. “We need to talk to the FDA about going directly into a phase three pivotal study,” he said, a conversation planned for the first half of 2026.